- Home
- SPIR vs AVTX Comparison
SPIR vs AVTX Comparison
Compare SPIR & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPIR | AVTX |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.5M | 982.5M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SPIR | AVTX |
|---|---|---|
| Price | $13.83 | $19.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $16.40 | ★ $40.57 |
| AVG Volume (30 Days) | 731.1K | ★ 800.3K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.98 | 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $110,451,000.00 | $27,813,137.00 |
| Revenue This Year | $12.31 | N/A |
| Revenue Next Year | $22.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 13.15 | ★ 2312.27 |
| 52 Week Low | $6.60 | $8.41 |
| 52 Week High | $25.93 | $24.27 |
Technical Indicators
Market Signals| Indicator | SPIR | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 55.56 |
| Support Level | $10.30 | $17.40 |
| Resistance Level | $14.99 | $20.68 |
| Average True Range (ATR) | 0.96 | 1.20 |
| MACD | 0.50 | 0.01 |
| Stochastic Oscillator | 72.49 | 76.37 |
Price Performance
Historical ComparisonAbout SPIR Spire Global Inc.
Spire Global Inc provides space-based data, analytics, and space services, offering datasets and insights about Earth to support decision-making. It builds, owns, and operates a constellation of nanosatellites that observe the Earth in real time using radio frequency (RF) technology. Additionally, it offers Space Services solutions that allow customers to deploy and scale their own satellite constellations using its platform, ground station network, manufacturing facilities, and launch partnerships. The company derives revenue from providing data, insights and access to its cloud-based technology platform sold on a subscription basis.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.